411 research outputs found
Immunoscintigraphy for therapy decision making and follow-up of biological therapies
With the availability of new biological therapies there is the need of more accurate diagnostic tools to noninvasively
assess the presence of their targets. In this scenario nuclear medicine offers many radiopharmaceuticals for
SPECT or PET imaging of many pathological conditions. The availability of monoclonal antibodies provides tools to
target specific antigens involved in angiogenesis, cell cycle or modulation of the immune systems. The radiolabelling of
such therapeutic mAbs is a promising method to evaluate the antigenic status of each cancer lesion or inflamed sites
before starting the therapy. It may also allow to perform follow-up of such biological therapies. In the present review we
provide an overview of the most studied radiolabelled antibodies for therapy decision making and follow-up of patients
affected by cancer and other pathological conditions
Reply to comment by J.P. Suarez Fernandez on "Consensus document for the diagnosis of prosthetic joint infections:a joint paper by the EANM, EBJIS, and ESR (with ESCMID endorsement)"
Radiolabelled cytokines for imaging chronic inflammation
Diagnosis and particularly follow-up of chronic inflammatory disorders could be often difficult in clinical practice. Indeed, traditional radiological techniques reveal only structural tissue alterations and are not able to monitor functional changes occurring in tissues affected by chronic inflammation. The continuous advances in the knowledge of the pathophysioloy of chronic disorders, combined with the progress of radiochemistry, led to the development of new specific radiolabelled agents for the imaging of chronic diseases. In this scenario, cytokines, due to their pivotal role in such diseases, represent good candidates as radiopharmaceuticals
Diabetic Foot Infections:The Diagnostic Challenges
Diabetic foot infections (DFIs) are severe complications of long-standing diabetes, and they represent a diagnostic challenge, since the differentiation between osteomyelitis (OM), soft tissue infection (STI), and Charcot's osteoarthropathy is very difficult to achieve. Nevertheless, such differential diagnosis is mandatory in order to plan the most appropriate treatment for the patient. The isolation of the pathogen from bone or soft tissues is still the gold standard for diagnosis; however, it would be desirable to have a non-invasive test that is able to detect, localize, and evaluate the extent of the infection with high accuracy. A multidisciplinary approach is the key for the correct management of diabetic patients dealing with infective complications, but at the moment, no definite diagnostic flow charts still exist. This review aims at providing an overview on multimodality imaging for the diagnosis of DFI and to address evidence-based answers to the clinicians when they appeal to radiologists or nuclear medicine (NM) physicians for studying their patients
Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha
Immune cell labelling and tracking. implications for adoptive cell transfer therapies
BACKGROUND: The understanding of the role of different immune cell subsets that infiltrate tumors can help researchers in developing new targeted immunotherapies to reactivate or reprogram them against cancer. In addition to conventional drugs, new cell-based therapies, like adoptive cell transfer, proved to be successful in humans. Indeed, after the approval of anti-CD19 CAR-T cell therapy, researchers are trying to extend this approach to other cancer or cell types.MAIN BODY: This review focuses on the different approaches to non-invasively monitor the biodistribution, trafficking and fate of immune therapeutic cells, evaluating their efficacy at preclinical and clinical stages. PubMed and Scopus databases were searched for published articles on the imaging of cell tracking in humans and preclinical models.CONCLUSION: Labelling specific immune cell subtypes with specific radiopharmaceuticals, contrast agents or optical probes can elucidate new biological mechanisms or predict therapeutic outcome of adoptive cell transfer therapies. To date, no technique is considered the gold standard to image immune cells in adoptive cell transfer therapies
Role of scintigraphy with 99mTc-infliximab in predicting the response of intraarticular infliximab treatment in patients with refractory monoarthritis
- …